After insurers were mandated to cover at-home Covid-19 tests, more people tested at-home screenings for other conditions. As preventive tests declined significantly during the pandemic, insurers also turned to creative means to give people access.
Ellume, whose at-home Covid-19 test was cleared by the FDA in December, got a $232 million contract from the Department of Health and Human Services to deliver 8.5 million tests.
Sandoz to Launch Hyrimoz (biosimilar, adalimumab) in Canada Published: Dec 17, 2020 | Tags: Authorization, Biosimilar, canada, health, Humira, Hyrimoz, Launch, receives, Sandoz Amgen’s Riabni (biosimilar, rituximab) Receives the US FDA’s Approval for Multiple Diseases Published: Dec 17, 2020 | Tags: Adult, Amgen, approval, Biosimilar,… Read More »PharmaShots Weekly Snapshots (Dec 14-18, 2020)
Shots: The US FDA has granted EUA for Ellume COVID-19 home test for non-prescription home use in symptomatic and asymptomatic individuals aged ≥2yrs. The data submitted to the US FDA from an independently run, simulated home-setting clinical study of 198 subjects aged 2-82yrs, demonstrated 96%… Read More »Ellume’s COVID-19 Home Test Receives the US FDA’s EUA as First Over-the-Counter Diagnostic Test
The FDA authorized an at-home antigen test for Covid-19 developed by Ellume. It does not require a prescription.